AFT has an R&D collaboration with Belgium's Hyloris Pharmaceuticals to develop a novel innovative injectable iron deficiency therapy. The company's product line extends to over 130 prescription and non-prescription products in Australasia with offices in Singapore, Kuala Lumpur, Sydney and Auckland. AFT exports or licenses products to over 109 countries.
Cyborg Score Rationale
AFT reported strong first-half performance for the six months to 30 September 2025 with revenue growing 3%, tracking in line with the $300 million FY27 revenue target. The company demonstrates solid innovation with FDA approvals and strategic partnerships while maintaining profitable operations.
Top Insights
US FDA approved Maxigesic IV, representing the company's second FDA approval within one year.
Hikma Pharmaceuticals' first sale of Maxigesic IV triggered a US$6 million license fee payment to AFT.
Product portfolio includes over 130 prescription and non-prescription products across therapeutic categories.
Global reach extends to over 109 countries through export and licensing agreements.